StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie adjusted R&D Expense % of Net Revenues — Non-GAAP (%) (%)

Form 8-K Earnings Release

Latest, Q2 2026
13.6%
Period ended Jun 30, 2026
Change on a year earlier
-0.1 pts
13.7% in Q2 2025
History
11 quarters
Since Q3 2022
Sources
11
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). AbbVie Adjusted R&D Expense % of Net Revenues — Non-GAAP (%) (%), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd_adj_pct_rev

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.